On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Learning objectives
- Why talk about IBD?
- Increasing incidence & prevalence of IBD
- IBD in the young
- The changing “face” of IBD
- The heavier you are, the worse you do
- The history: Systemic complications
- EIMs in IBD: Overall prevalence
- Not everything is Crohn’s: Small bowel mimics
- Right sided colonic thickening: Crohn’s?
- Therapeutic pyramid
- Site of oral mesalamine release
- Comedications in IBD
- Laboratory testing: Medication dependent
- Anti-TNF agents: Adverse events
- Anti-TNF: Side effect profile
- “Can I stop my medicine?”
- Predictors of rapid progression to surgery
- Factors of poor outcome in UC
- Role of patient perception
- CAM and IBD
- Herbal supplements
- Vitamin D and disease activity
- Cannabis usage in CD
- Vaccines
- Live vaccinations
- Pneumococcal vaccination in IBD patients on immune suppressants
- Depression
- Risks of dysplasia or CRC in UC
- Summary
- Disclosure of financial relationships
Topics Covered
- Clinical epidemiology and characteristics of IBD
- Diagnostic testing
- Medical treatment of UC and CD
- Adverse events with medications
- Assessing extraintestinal manifestations of IBD
- Complications of disease
- Alternative Therapies for IBD
- Vaccination advice
- Mental health issues
- Cancer screening
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kane, S. (2021, May 30). IBD for the non-gastroenterologist [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/VYEA4824.Export Citation (RIS)
Publication History
- Published on May 30, 2021
Financial Disclosures
- Prof. Sunanda Kane, Consultant: Abbot, Elam, Shire, UCB / Grant/Research Support (Principal Investigator): Elam, Shire.
A selection of talks on Immunology & Inflammation
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I am Dr. Sunanda Kane,
professor of medicine and gastroenterologist at Mayo Clinic in Rochester,
Minnesota in the United States.
Today we're going to talk about inflammatory bowel
disease (IBD) for the non-gastroenterologist.
0:17
Today, our learning objectives include: understanding the changing epidemiology of IBD;
recognizing some common mimics, of Crohn's disease in particular;
appreciating the therapeutic monitoring for IBD;
and being comfortable with non-therapeutic management issues in the IBD patient.
0:38
Why should we talk about IBD at all for the non-gastroenterologist?
It's very interesting that there was a nice epidemiologic study done looking
at the care of IBD patients from 1998 through 2005.
During this time, there was a 450 percent increase in visits to
primary care physicians by Crohn's patients, and
350 percent by ulcerative colitis patients.
The decrease in Crohn's disease patients for 5-ASA use was seven percent,
steroid use was decreased by 36 percent in Crohn's and 27 percent in ulcerative colitis.
The good news here was a decrease in hospitalizations by
33 percent in Crohn's patients and almost the same in ulcerative colitis,
then the decrease in surgery didn't change for Crohn's,
but there was a 50 percent decrease in surgery rates for ulcerative colitis over
this timeframe when there was a parallel in increased visits to primary care physicians.
Clearly, there is a signal here that primary care is as important as,
if not more important
than, the care from a gastroenterologist in terms of outcomes and treatment.